Morgan Stanley flags Amgen's edge after heart-drug rival stumbles
Amgen’s (AMGN) closely watched cardiovascular drug candidate lost a major rival on Sept. 4, when Novartis (NVS) announced that its pelacarsen trial failed to reduce heart attacks and strokes in high-risk patients.
22 Sep 00:07 · The Fresno Bee